BRAF and melanoma: Inhibition of mutant BRAF (V600E) activity by either the BRAF inhibitor Vemurafenib (PLX4032, Supplementary Fig. 3a) or BRAF siRNA markedly reduced the LNK transcript levels in melanoma A375 cells (Supplementary Fig. 3b), while forced expression of an activated BRAF (V600E) generated the opposite effect (~four-fold increased LNK, Supplementary Fig. 3c).